Current Gene Therapy

Top Research Topics at Current Gene Therapy?

Current Gene Therapy facilitates discussions on Genetic enhancement, Immunology, Gene delivery, Viral vector and Gene. In addition to Genetic enhancement research, Current Gene Therapy aims to explore topics under Transgene, Bioinformatics, Virology, Vector (molecular biology) and Computational biology. It facilitates discussions on Bioinformatics that incorporate concepts from other fields like Disease and Pathology.

While work presented in Current Gene Therapy provided substantial information on Virology, it also covered topics in Adeno-associated virus and Transduction (genetics). The Computational biology study featured in it draws connections with the study of Genome. Current Gene Therapy explores issues in Immunology which can be linked to other research areas like Cancer research, Stem cell and Transplantation.

It addresses concerns in Cancer research which are intertwined with other disciplines, such as Cancer and In vivo. The study on Gene delivery presented in Current Gene Therapy intersects with subjects under the field of Cell biology. The presentations focused mostly on Gene in an attempt to further explore topics in Genetics.

• Genetic enhancement (52.88%)
• Immunology (23.34%)
• Gene delivery (19.98%)

What are the most cited papers published in the journal?

• New recombinant serotypes of AAV vectors. (430 citations)
• Altering the tropism of lentiviral vectors through pseudotyping. (408 citations)
• From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy (311 citations)

Research areas of the most cited articles at Current Gene Therapy:

Genetic enhancement, Computational biology, Viral vector, Gene delivery and Virology are the main subjects of interest in the most cited papers. While work presented in the journal publications provide substantial information on Genetic enhancement, it also covers topics in Transgene, Vector (molecular biology) and Immunology, Immune system. The works on Gene delivery tackled in the published articles bring together disciplines like In vivo and Cell biology.

What topics the last edition of the journal is best known for?

• Gene
• Cancer
• DNA

The previous edition focused in particular on these issues:

Current Gene Therapy investigates studies in Genetic enhancement, Cancer research, Bioinformatics, Gene and Disease. The studies in Genetic enhancement featured incorporate elements of Vector (molecular biology), Adeno-associated virus, Immune system, Viral vector and Computational biology. Vector (molecular biology) research featured in the journal incorporates concerns from various other topics such as Therapeutic effect, Target gene, Central nervous system and Gene delivery.

The Immune system research discussed is included in the broader subject of Immunology. The Cancer research works featured in Current Gene Therapy incorporate elements from Cell, Haematopoiesis, Mesenchymal stem cell, Targeted therapy and Flow cytometry. Topics in Gene explored in Current Gene Therapy were investigated in conjunction with research in Therapeutic approach and Mutation (genetic algorithm).

The most cited articles from the last journal are:

• Identification of Chronic Hypersensitivity Pneumonitis Biomarkers with Machine Learning and Differential Co-expression Analysis. (4 citations)
• Mesenchymal Stem Cells Promote Caspase Expression in Molt-4 Leukemia Cells Via GSK-3α/Β and ERK1/2 Signaling Pathways as a Therapeutic Strategy. (4 citations)
• Molecular Genetics of Early- and Late-Onset Alzheimer's Disease. (2 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

Top authors and change over time

The top authors publishing in Current Gene Therapy (based on the number of publications) are:

• Ignacio Anegon (11 papers) absent at the last edition,
• Axel Schambach (9 papers) absent at the last edition,
• Marie-Pierre Rols (9 papers) absent at the last edition,
• Mark Tangney (8 papers) absent at the last edition,
• Ryuichi Morishita (8 papers) absent at the last edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Top affiliations and change over time

Only papers with recognized affiliations are considered

The top affiliations publishing in Current Gene Therapy (based on the number of publications) are:

• French Institute of Health and Medical Research (18 papers) absent at the last edition,
• University of Florida (16 papers) absent at the last edition,
• Hannover Medical School (14 papers) absent at the last edition,
• Sichuan University (14 papers) published 1 paper at the last edition, 5 less than at the previous edition,
• University of California, Los Angeles (13 papers) absent at the last edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 3.51% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 1.82% were posted by at least one author from the top 10 institutions publishing in the journal. Another 14.55% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 10.91% of all publications and 72.73% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

• Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
• Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
• Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
• Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
• Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Career Opportunities in Gene Therapy Research

All these exciting developments in gene therapy research open up a plethora of career opportunities for aspiring scientists and researchers. Those interested in this field require specialized education and training. Some may even choose to become licensed pharmacists, taking an active part in gene therapy treatment methods.

If you are considering a career in the pharmaceutical aspect of gene therapy, check out our comprehensive guide on how to become a pharmacist in New Jersey. This guide will provide you with a thorough understanding of the educational and training requirements, steps to licensure, and future prospects in the sphere of pharmacy, setting you up for a potential role in the development and application of gene therapy treatments.

Whether it's conducting ground-breaking research, translating that research into viable treatments, or liaising directly with patients as part of a healthcare team, the opportunities in gene therapy are as diverse as they are rewarding.